Stocktoria

Viskase Holdings, Inc. ENZN

OTC · OOTC · stock · Biological Products, (No Diagnostic Substances) · website · IPO 1984-02-16

Viskase Holdings, Inc. financials (annual, from 10-K)

Revenue
2016201720182019202020212022202320242025
Net income
2016201720182019202020212022202320242025
Free cash flow
2016201720182019202020212022202320242025

Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).

MetricFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$26,000$26,000$701,000$52,000$207,000$6.9M$8.4M$8.4M
Operating income-$5.3M-$1.3M-$1.0M-$1.0M-$469,000-$1.3M-$973,000
Income tax$19,000$347,000-$156,000-$200,000$7,000$7,000$6,000$6,000$1.6M$7.8M
Net income-$3.4M$778,000$1.4M-$186,000-$469,000-$1.3M-$979,000$5.8M$5.4M-$1.1M
EPS (diluted)$-0.07$-0.01$0.00$-0.02$-0.03$-0.03$0.12$-0.03
Operating cash flow-$3.0M$1.1M$1.3M-$659,000-$501,000-$380,000$6.9M-$978,000$6.5M$2.6M
Cash & equivalents$9.2M$46.9M$47.0M$47.0M$47.6M$48.1M$5.4M$6.5M$7.5M$7.6M
Inventory$96.8M
Total assets$402.1M$47.2M$47.7M$47.6M$47.8M$48.2M$6.5M$15.5M$9.5M$11.3M
Shareholders' equity$145.8M$170.0M-$3.5M$3.4M$4.9M$7.4M$6.1M$15.0M$9.1M$10.3M

Growth · year-over-year · Revenue CAGR -56.2%

MetricFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue growth-96.3%+1248.1%-74.9%-97.0%-17.4%+0.0%-52.0%
Net income growth-538.2%-43.3%-116.7%+7.4%-105.2%
EPS growth-106.1%

Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.

Source: SEC EDGAR filings · CIK 0000727510 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.